Raloxifene Protects Oxygen-Glucose-Deprived Astrocyte Cells Used to Mimic Hypoxic-Ischemic Brain Injury

Area of Science:

• Neuroscience
• Cell Biology
• Pharmacology

Background:

• Perinatal asphyxia (PA) is a significant cause of neurodevelopmental damage, particularly in developing countries.
• Current therapeutic options for PA-induced harm are limited.
• Selective estrogen receptor modulators, such as raloxifene, have shown neuroprotective effects in other conditions.

Purpose of the Study:

• To investigate the potential neuroprotective effects of raloxifene in an in vitro model of perinatal asphyxia.
• To evaluate raloxifene's impact on astrocyte survival and mitochondrial function under oxygen-glucose deprivation and reoxygenation.

Main Methods:

• Primary astrocyte cell cultures (T98G) were subjected to oxygen-glucose deprivation (OGD) for 3, 6, 12, and 24 hours.
• Cells were co-treated with raloxifene (10 and 100 nM) during OGD and reoxygenation.
• Cell survival, mitochondrial membrane potential, superoxide production, peroxide production, and mitochondrial mass were assessed.

Main Results:

• Raloxifene significantly improved astrocyte survival at both 10 nM (70.56%) and 100 nM (65.34%) concentrations.
• Mitochondrial membrane potential was preserved by raloxifene, with 100 nM showing an 81.57% increase.
• Raloxifene reduced reactive oxygen species (ROS) production and lipid peroxidation, indicating direct mitochondrial protection.

Conclusions:

• Raloxifene exhibits significant neuroprotective properties in an in vitro model mimicking perinatal asphyxia.
• The drug enhances astrocyte survival and preserves mitochondrial function.
• These findings suggest raloxifene as a potential therapeutic agent for hypoxic-ischemic brain injury associated with perinatal asphyxia.